Cilengitide in Subjects With Newly Diagnosed Glioblastoma and Unmethylated MGMT Gene Promoter - a Multicenter, Open-label Phase II Study, Investigating Two Cilengitide Regimens in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy). [The CORE Study]

Trial Profile

Cilengitide in Subjects With Newly Diagnosed Glioblastoma and Unmethylated MGMT Gene Promoter - a Multicenter, Open-label Phase II Study, Investigating Two Cilengitide Regimens in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy). [The CORE Study]

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Cilengitide (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms CORE
  • Sponsors Merck KGaA
  • Most Recent Events

    • 19 Jan 2016 Pooled analysis of 4 studies (n=1869) including data from this study and 3 other trials (see CTP 700046838, 700038467, 700034867) were published in the Journal of Clinical Oncology.
    • 24 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 01 Oct 2012 Planned end date changed from 1 Jun 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top